Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy
Source: SeekingAlpha
2026-03-10 21:01:15 ET
More on Skye Bioscience
- Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
- Skye Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Seeking Alpha’s Quant Rating on Skye Bioscience
- Historical earnings data for Skye Bioscience
- Financial information for Skye Bioscience
Read the full article on Seeking Alpha
For further details see:
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy
Skye Bioscience Inc Com
NASDAQ: SKYE
SKYE Trading
-9.68% G/L:
$0.6922 Last:
1,115,022 Volume:
$0.66 Open:
SKYE Latest News
March 10, 2026 04:01:00 pm
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 05, 2026 07:00:00 am
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
February 02, 2026 07:00:00 am
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
SKYE Stock Data
$23,264,099
19,202,419
2.95%
18
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
